Refine
Has Fulltext
- yes (28)
Is part of the Bibliography
- yes (28)
Year of publication
Document Type
- Doctoral Thesis (28)
Keywords
- miRNS (5)
- SMN (4)
- Genexpression (3)
- Messenger-RNS (3)
- Small nuclear RNP (3)
- Biogenese (2)
- Messenger-RNP (2)
- Multiproteinkomplex (2)
- RNS (2)
- SMN complex (2)
Institute
- Graduate School of Life Sciences (18)
- Lehrstuhl für Biochemie (9)
- Fakultät für Biologie (3)
- Fakultät für Chemie und Pharmazie (2)
- Institut für Organische Chemie (2)
- Institut für Klinische Neurobiologie (1)
- Institut für Molekulare Infektionsbiologie (1)
- Medizinische Fakultät (1)
- Neurologische Klinik und Poliklinik (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Sonstige beteiligte Institutionen
An essential step in eukaryotic gene expression is splicing, i.e. the excision of non-coding sequences from pre-mRNA and the ligation of coding-sequences. This reaction is carried out by the spliceosome, which is a macromolecular machine composed of small nuclear ribonucleoproteins (snRNPs) and a large number of proteins. Spliceosomal snRNPs are composed of one snRNA (or two in case of U4/6 snRNPs), seven common Sm proteins (SmD1, D2, D3, B, E, F, G) and several particle-specific proteins. The seven Sm proteins form a ring shaped structure on the snRNA, termed Sm core domain that forms a structural framework of all spliceosomal snRNPs. In the toroidal Sm core domain, the individual Sm proteins are arranged in the sequence SmE-SmG-SmD3-SmB- SmD1-SmD2-SmF from the first to the seventh nucleotide of the Sm site, respectively. The individual positions of Sm proteins in the Sm core domain are not interchangeable.
snRNPs are formed in vivo in a step-wise process, which starts with the export of newly transcribed snRNA to the cytoplasm. Within this compartment, Sm proteins are synthesized and subsequently transferred onto the snRNA. Upon formation of the Sm core and further modifications of snRNA, the snRNP is imported into the nucleus to join the spliceosome.
Prior to assembly into snRNPs, Sm proteins exist as specific hetero-oligomers in the cytoplasm. The association of these proteins with snRNA occurs spontaneously in vitro but requires the assistance of two major units, PRMT5- and SMN- complexes, in vivo. The early phase of assembly is critically influenced by the assembly chaperone pICln. This protein pre-organizes Sm proteins to functional building blocks and enables their recruitment onto the PRMT5 complex for methylation. Sm proteins are subsequently released from the PRMT5 complex as pICln bound entities and transferred onto the SMN-complex. The SMN complex then liberates the Sm proteins from the pICln-induced kinetic trap and allows their transfer onto the snRNA. Although the principal roles of SMN- and PRMT5 complexes in the assembly of snRNPs have been established, it is still not clear how newly translated Sm proteins are guided into the assembly line.
In this thesis, I have uncovered a new facet of pICln function in the assembly of snRNPs. I have shown that newly synthesized Sm proteins are retained at the ribosome upon termination of translation. Their release is facilitated by pICln, which interacts with the cognate Sm protein hetero-oligomers at their site of synthesis on the ribosome and recruits them into the assembly pathway. Additionally, I have been able to show that the early engagement of pICln with the Sm proteins ensures the flawless oligomerization of Sm proteins and prevents any non-chaperoned release and diffusion of Sm proteins in the cytoplasm.
In a second project, I have studied the mechanism of U7 snRNP assembly. This particle is a major component of the 3’ end processing machinery of replication dependent histone mRNAs. A biochemical hallmark of U7 is its unique Sm core in which the two canonical Sm proteins D1 and D2 are replaced by so-called “like Sm proteins”. The key question I addressed in my thesis was, how this “alternative” Sm core is assembled onto U7 snRNA. I have provided experimental evidence that the assembly route of U7 snRNPs and spliceosomal snRNPs are remarkably similar: The assembly of both particles depends on the same assembly factors and the mechanistic details are similar. It appears that formation of the U7- or spliceosomal- core specific 6S complex is the decisive step in assembly.
While TGF-β is able to regulate miRNA expression in numerous cell types, TGF-β-dependent changes in the miRNA profile of CD8+ T cells had not been studied before. Considering that TGF-β suppresses CD8+ T cell effector functions in numerous ways, we wondered whether induction of immune-regulatory miRNAs could add to the known transcriptional effects of TGF-β on immune effector molecules. In this study, we used miRNA arrays, deep sequencing and qRT-PCR to identify miRNAs that are modulated by TGF-β in human CD8+ T cells. Having found that the TGF-β-dependent downregulation of NKG2D surface expression in NK cells and CD8+ T cells does not go along with a corresponding reduction in mRNA levels, this pathway appeared to be a possible target of TGF-β-inducible miRNAs. However, this hypothesis could not be confirmed by miRNA reporter assays. Instead, we observed that DAP10 transcription is suppressed by TGF-β which in turn negatively affects NKG2D surface expression. In spite of promising preliminary experiments, technical difficulties associated with the transfection of primary NK cells and NK cell lines unfortunately precluded the final proof of this hypothesis.
Instead, we focused on the TGF-β-induced changes in the miRNome of CD8+ T cells and confirmed the induction of the miR-23a cluster members, namely miR-23a, miR-27a and miR-24 by three different techniques. Searching for potential targets of these miRNAs which could contribute to the immunosuppressive action of TGF-β in T cells, we identified and confirmed a previously unknown regulation of IFN-γ mRNA by miR-27a and miR-24. Newly generated miRNA reporter constructs further revealed that LAMP1 mRNA is a target of miR-23a. Upon modulation of the miR-23a cluster in CD8+ T cells by the respective miRNA antagomirs and mimics, significant changes in IFN-γ expression confirmed the functional relevance of our findings. Effects on CD107a/LAMP1 expression were, in contrast, rather minimal. Still, overexpression of the miR-23a cluster attenuated the cytotoxic activity of antigen-specific CD8+ T cells. Taken together, these functional data reveal that the miR-23a cluster not only is induced by TGF-β, but also exerts a suppressive effect on CD8+ T-cell effector functions, even in the absence of TGF-β signaling.
MicroRNAs are endogenous ≈22 nt long non coding RNA molecules that modulate gene expression
at the post transcriptional level by targeting mRNAs for cleavage or translational repression.
MicroRNA-mRNA interaction involves a contiguous and perfect pairing within complementary
sites usually in the 3’ UTR of the target mRNA. Heart failure is associated with myocyte
hypertrophy and death, due to compensatory pathological remodeling and minimal functional repair
along with microRNA deregulation.
In this study, we identified candidate microRNAs based on their expression strength in
cardiomyocytes and by their ability to regulate hypertrophy. Expression profiling from early and
late stages of heart failure showed several deregulated microRNAs. Of these microRNAs, miR-378
emerged as a potentially interesting microRNA that was highly expressed in the mouse heart and
downregulated in the failing heart. Antihypertrophic activity of miR-378 was first observed by
screening a synthetic miR library for morphologic effects on cardiomyocytes, and validated in vitro proving the tight control of hypertrophy by this miR. We combined bioinformatic target prediction analysis and microarray analysis to identify the targets of miR-378. These analyses suggested that factors of the MAP kinase pathway were enriched among miR-378 targets, namely MAPK1 itself (also termed ERK2), the insulin-like growth factor receptor 1 (IGF1R), growth factor receptor bound protein 2 (GRB2) and kinase suppressor of ras 1 (KSR1). Regulation of these targets by miR-378 was then confirmed by mRNA and protein expression analysis. The use of luciferase reporter constructs with natural or mutated miR-378 binding sites further validated these four proteins as direct targets of miR-378. RNA interference with MAPK1 and the other three targets prevented the prohypertrophic effect of antimiR-378, suggesting that they functionally relate to miR-378. In vivo restoration of disease induced loss of miR-378 in a pressure overload mouse model of hypertrophy using adeno associated virus resulted in partial attenuation cardiac hypertrophy and significant improvement in cardiac function along with reduced expression of the four targets in heart.
We conclude from these findings that miR-378 is an antihypertrophic microRNA in cardiomyocytes, and the main mechanism underlying this effect is the suppression of the MAP kinase-signaling pathway on four distinct levels. Restoration of disease-associated loss of miR-378 through cardiomyocyte-targeted AAV-miR-378 may prove as an effective therapeutic strategy in myocardial disease.
Eukaryotische messenger-RNAs (mRNAs) müssen diverse Prozessierungsreaktionen durchlaufen, bevor sie der Translationsmaschinerie als Template für die Proteinbiosynthese dienen können. Diese Reaktionen beginnen bereits kotranskriptionell und schließen das Capping, das Spleißen und die Polyadenylierung ein. Erst nach dem die Prozessierung abschlossen ist, kann die reife mRNA ins Zytoplasma transportiert und translatiert werden. mRNAs interagieren in jeder Phase ihres Metabolismus mit verschiedenen trans-agierenden Faktoren und bilden mRNA-Ribonukleoproteinkomplexe (mRNPs) aus. Dieser „mRNP-Code“ bestimmt das Schicksal jeder mRNA und reguliert dadurch die Genexpression auf posttranskriptioneller Ebene.
Für das La-verwandte Protein LARP4B (La-related protein 4B) wurde kürzlich eine direkte Interaktion mit den Translationsfaktoren PABPC1 (poly(A) binding protein, cytoplasmic 1) und RACK1 (receptor for activated C kinase) gefunden. Diese Befunde sowie die Assoziation mit aktiv translatierenden Ribosomen lässt vermuten, dass LARP4B zum mRNP-Code beiträgt. Die Domänenstruktur des Proteins legt darüber hinaus nahe, dass LARP4B direkt mRNAs bindet.
Um einen Einblick in die Funktion von LARP4B und seiner in vivo RNA-Bindungspartner zu erhalten, wurde die mRNA-Assoziation transkriptomweit mit Hilfe von PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation)-Experimenten bestimmt. Diese Daten zeigten, dass LARP4B ein spezifisches Set an zellulären mRNAs über Sequenzbereiche in deren 3’-untranslatierten Regionen bindet. Die bioinformatische Auswertung der PAR-CLIP-Daten identifizierte ein LARP4B-Bindemotiv, welches durch in vitro Bindungsstudien validiert werden konnte. Darüber hinaus belegten pSILAC (pulsed stable isotope labeling with amino acids in cell culture)-Experimente und eine transkriptomweite Analyse der mRNA-Level, dass LARP4B die Expression der Ziel-mRNAs beeinflusst, indem es die Stabilität der gebundenen Transkripte erhöht. LARP4B konnte somit als positiver Faktor der eukaryotischen Genexpression identifiziert werden.
Galectin-1 (hGal-1) is overexpressed by numerous cancer types and previously conducted studies confirmed that the β-galactoside-binding protein mediates various molecular interactions associated with tumor growth, spread and survival. Upon interaction with carbohydrate-based binding epitopes of glycan structures on human cell surfaces galectin-1 induces proliferative, angiogenetic and migratory signals and modulates negative T cell regulation which essentially helps the tumor to evade the immune response. These findings attributed galectin-1 a pivotal role in tumor physiology and strongly suggest the protein as target for diagnostic and therapeutic applications.
Within the scope of this work a strategy was elaborated for designing tailor-made galectin-1 ligands by functionalizing selected hydroxyl groups of the natural binding partner N-acetyllactosamine (LacNAc) that are not involved in the sophisticated interplay between the disaccharide and the protein. Synthetic modifications intended to introduce chemical groups i) to address a potential binding site adjacent to the carbohydrate recognition domain (CRD) with extended hGal-1-ligand interactions, ii) to implement a tracer isotope for diagnostic detection and iii) to install a linker unit for immobilization on microarrays.
Resulting structures were investigated regarding their targeting ability towards galectin-1 by cocrystallization experiments, SPR and ITC studies. Potent binders were further probed for their diagnostic potential to trace elevated galectin-1 levels in microarray experiments and for an application in positron emission tomography (PET).
Das Spleißen von prä-mRNAs stellt in der Expression eukaryontischer Gene einen essentiellen Reifungsschritt dar. Erst durch das exakte Entfernen von nicht-kodierenden Introns und Verbinden der kodierenden Exons kann die genetische Information am Ribosom in funktionelle Proteine umgesetzt werden. Spleißen wird durch das Spleißosom katalysiert, welches sich aus den small nuclear ribonucleoproteins (snRNPs) U1, U2, U4, U5 und U6 und einer großen Anzahl weiterer Proteinfaktoren zusammensetzt. Die snRNPs bestehen aus einer Uridin-reichen snRNA, spezifischen und generellen (Sm-)Proteinen. Die Sm-Proteine B/B`, D1, D2, D3, E, F, und G bilden einen heptameren Ring um die sog. Sm-Bindungsstelle der snRNAs. Während die Zusammenlagerung von Sm-Proteinen mit der RNA in vitro spontan ablaufen kann, wird dieser Prozess in vivo von zwei makromolekularen Proteinkomplexen assistiert, die als PRMT5- bzw. SMN-Komplex bezeichnet werden. Der PRMT5-Komplex (bestehend aus PRMT5, WD45 und pICln) agiert in der frühen Phase der Zusammenlagerung. Seine Hauptfunktion ist die symmetrische Dimethylierung der Sm-Proteine und die Stabilisierung von Sm-Proteinkomplexen durch das Chaperon pICln in zwei Intermediaten. Einhergehend mit dieser Aktivität werden auch Aggregation bzw. unspezifische Wechselwirkungen der Sm-Proteine mit RNAs verhindert. In der späten Phase der Zusammenlagerung löst der SMN-Komplex (bestehend aus SMN, Gemin2-8 und unrip) pICln-Intermediate auf, wobei dieser die Sm-Proteine en bloc übernimmt und sie auf die snRNA überträgt. Während dieser Reaktion wird pICln aus den Komplexen verdrängt. Ein Fehlen des SMN-Proteins, einer Schlüsselkomponente des SMN-Komplexes, führt zur autosomal rezessiven Erbkrankheit `Spinale Muskelatrophie` (SMA) wobei der Schweregrad der Krankheit invers mit der Menge an funktionellem SMN-Protein korreliert. Es wird vermutet, dass eine gestörte snRNP-Biogenese die Ursache der SMA ist.
In der vorliegenden Arbeit sollte die U snRNP-Zusammenlagerungsmaschinerie aus rekombinanten Bausteinen rekonstituiert werden und so funktionellen und strukturellen Studien zugänglich gemacht werden. Folgende Resultate wurden in dieser Arbeit erhalten:
1) Im ersten Teil der Arbeit wurde eine experimentelle Strategie etabliert, welche die Rekonstitution des humanen SMN-Komplexes aus rekombinanten Untereinheiten erlaubte. Entscheidend hierfür war die Definition von Subkomplexen aufgrund einer Protein-Interaktionskarte. Die Subkomplexe konnten separat hergestellt und anschließend zum Gesamtkomplex vereinigt werden.
2) Die erfolgreiche Etablierung eines rekonstitutiven Systems erlaubte eine detaillierte biochemische Charakterisierung des SMN-Komplexes. Es konnte gezeigt werden, dass der rekombinante Komplex alle für die Biogenese von U snRNPs nötigen Schritte bewerkstelligen konnte. Dies schließt sowohl die Übernahme der Sm-Proteine aus den pICln-Intermediaten als auch das Verdrängen des Chaperons pICln und die Übertragung der Sm-Proteine auf die snRNAs ein.
3) Durch die Reduzierung des SMN-Gesamtkomplexes um Gemin3-5 auf einen SMN-Pentamer konnte dieser als ein funktioneller Kernbereich identifiziert werden, der die einzelnen Schritte der U snRNP-Biogenese vergleichbar mit dem gesamten Komplex bewerkstelligen konnte. Zudem agierte dieser reduzierte Komplex als notwendiger und ausreichender Spezifitätsfaktor der RNP-Zusammenlagerung.
4) Das rekombinante System ermöglichte erstmals SMN-Komplexe mit SMA-pathogenen Mutationen herzustellen und einer eingehenden funktionellen und strukturellen Untersuchung zu unterziehen. Die detaillierte Analyse der SMA-verursachenden Punktmutation SMN(E134K) offenbarte spezifische Defekte im Zusammenlagerungsprozess und damit Einblicke in die Pathophysiologie der Krankheit.
Mit der im Rahmen dieser Arbeit etablierten Rekonstitution des rekombinanten SMN-Komplexes wurde die Grundlage für die detaillierte biochemische und strukturbiologische Untersuchung der Zusammenlagerungsmaschinerie spleißosomaler U snRNPs gelegt. Dieses experimentelle System wird auch bei der Aufdeckung der biochemischen Defekte hilfreich sein, die zur neuromuskulären Krankheit SMA führen.
The propagation of the genetic information into proteins is mediated by messenger- RNA (mRNA) intermediates. In eukaryotes mRNAs are synthesized by RNA- Polymerase II and subjected to translation after various processing steps. Earlier it was suspected that the regulation of gene expression occurs primarily on the level of transcription. In the meantime it became evident that the contribution of post- transcriptional events is at least equally important. Apart from non-coding RNAs and metabolites, this process is in particular controlled by RNA-binding proteins, which assemble on mRNAs in various combinations to establish the so-called “mRNP- code”.
In this thesis a so far unknown component of the mRNP-code was identified and characterized. It constitutes a hetero-trimeric complex composed of the Tudor domain-containing protein 3 (TDRD3), the fragile X mental retardation protein (FMRP) and the Topoisomerase III beta (TOP3β) and was termed TTF (TOP3β-TDRD3-FMRP) -complex according to its composition.
The presented results also demonstrate that all components of the TTF-complex shuttle between the nucleus and the cytoplasm, but are predominantly located in the latter compartment under steady state conditions. Apart from that, an association of the TTF-complex with fully processed mRNAs, not yet engaged in productive translation, was detected. Hence, the TTF-complex is a component of „early“ mRNPs.
The defined recruitment of the TTF-complex to these mRNPs is not based on binding to distinct mRNA sequence-elements in cis, but rather on an interaction with the so-called exon junction complex (EJC), which is loaded onto the mRNA during the process of pre-mRNA splicing. In this context TDRD3 functions as an adapter, linking EJC, FMRP and TOP3β on the mRNP. Moreover, preliminary results suggest that epigenetic marks within gene promoter regions predetermine the transfer of the TTF-complex onto its target mRNAs.
Besides, the observation that TOP3β is able to catalytically convert RNA-substrates disclosed potential activities of the TTF-complex in mRNA metabolism. In combination with the already known functions of FMRP, this finding primarily suggests that the TTF-complex controls the translation of bound mRNAs.
In addition to its role in mRNA metabolism, the TTF-complex is interesting from a human genetics perspective as well. It was demonstrated in collaboration with researchers from Finland and the US that apart from FMRP, which was previously linked to neurocognitive diseases, also TOP3β is associated with neurodevelopmental disorders. Understanding the function of the TTF-complex in mRNA metabolism might hence provide important insight into the etiology of these diseases.
Durch die Spleißreaktion werden nicht-kodierende Sequenzelemente (Introns) aus eukaryotischen Vorläufer-mRNAs entfernt und die kodierenden Sequenzelemente (Exons) miteinander zu einem offenen Leserahmen verbunden. Dieser zentrale Prozessierungsschritt während der eukaryotischen Genexpression wird durch das Spleißosom katalysiert, das aus den vier kleinen nukleären Ribonucleoproteinpartikeln (snRNPs) U1, U2, U4/U6 und U5, sowie einer Vielzahl weiterer Proteinfaktoren gebildet wird. Alle snRNPs besitzen eine gemeinsame ringförmige Kernstruktur, die aus sieben gemeinsamen Sm-Proteinen (SmB/B‘-D1-D2-D3-E-F-G) besteht, die ein einzelsträngiges Sequenzmotiv auf der snRNAs binden. Während sich diese, als Sm-Core-Domäne bezeichnete Struktur in vitro spontan ausbilden kann, erfolgt die Zusammenlagerung in vivo in einem assistierten und hochregulierten Prozess. Dieser ist abhängig von insgesamt mindestens 12 trans-agierenden Faktoren, die in den PRMT5- und SMN-Komplexen organisiert sind. Der PRMT5-Komplex agiert in der frühen Phase der Zusammenlagerung, indem er die Sm-Proteine durch die Untereinheit pICln rekrutiert und die symmetrische Methylierung von Argininresten in den C terminalen Schwänzen von SmB/B‘, SmD1 und SmD3 katalysiert.
Als Resultat dieser frühen Phase befinden sich die Sm-Proteine SmD1-D2-E-F-G und SmB/B‘-D3 in zwei getrennten und durch pICln organisierten Komplexen. Während SmB/B‘-D3-pICln am PRMT5-Komplex gebunden bleibt, existiert der zweite Komplex als freies Intermediat mit einem Sedimentationskoeffizienten von 6S. Diese Intermediate können nicht mit RNA assoziieren, sodass für die Fortsetzung des Zusammenlagerungsprozesses die Interaktion der Sm-Proteine mit pICln aufgelöst werden muss. Dies geschieht in der späten Phase der Sm-Core-Zusammenlagerung, in der die Sm-Proteine vom SMN-Komplex (bestehend aus SMN, Gemin2-8 und unrip) übernommen werden und pICln dissoziiert wird. Dadurch werden die Sm-Proteine für ihre Interaktion mit der snRNA aktiviert und können auf die Sm-Bindestelle transferiert werden, wodurch die Formierung des Sm-Core abgeschlossen wird.
Im Rahmen dieser Arbeit konnten mit Hilfe einer Kombination röntgenkristallographischer und elektronenmikroskopischer Methoden zwei wichtige Intermediate dieses Zusammenlagerungs-prozesses strukturbiologisch charakterisiert werden. Bei diesen Intermediaten handelt es sich um den 6S-Komplex, sowie um ein Sm-Protein-Transferintermediat mit einem Sedimentations-koeffizienten von 8S. In diesem ist der 6S-Komplex an zwei zentrale Untereinheiten des SMN-Komplexes (SMN und Gemin2) gebunden, während pICln den Komplex noch nicht verlassen hat. Der 8S-Komplex stellt daher ein „gefangenes“ Intermediat zwischen der frühen und späten Phase der Zusammenlagerung dar.
Zunächst gelang es eine erste Kristallform des rekombinant hergestellten 8S-Komplexes zu erhalten, die jedoch keine Strukturlösung erlaubte. Durch eine kombinierte Optimierung der Kristallisationsbedingung und der verwendeten Proteine wurde eine weitere ähnliche Kristallform erhalten, mit der die Kristallstruktur des 8S-Komplexes gelöst werden konnte. Die Kristallisation des 6S-Komplexes gelang im Anschluss auf Basis der Hypothese, dass Kristalle beider Komplexe aufgrund der kompositionellen Verwandtschaft zwischen 6S und 8S auch Ähnlichkeiten in der Architektur ihrer Kristallgitter aufweisen könnten. Daher wurden innerhalb von pICln gezielt Aminosäuren substituiert, die sich innerhalb von Kristallkontakten der 8S-Kristalle befanden und konformationell eingeschränkt waren. Mit entsprechend rekonstituierten 6S-Präparationen konnten dann zwei Kristallformen erzeugt werden, die eine Strukturlösung des 6S-Komplexes ermöglichten.
Durch die Kristallstruktur des 6S-Komplexes konnte für pICln eine strukturelle Mimikry der Sm-Proteine identifiziert werden. Diese ermöglicht eine Bindung der Sm-Proteine und eine frühzeitige topologische Organisation des Sm-Pentamers D1-D2-F-E-G in einer geschlossenen hexameren Ringstruktur. Die Kristallstruktur des 8S-Komplexes zeigt, wie der SMN-Komplex über Gemin2 an das Sm-Pentamer bindet. In Kombination mit einer EM-Struktur des 8S-Komplexes gelang es weiterhin, einen plausiblen Mechanismus für die Elimination von pICln und die Aktivierung der Sm-Proteine für die snRNA-Bindung zu formulieren. Somit konnten diese Arbeiten zu einem besseren Verständnis der Funktionen von trans-agierenden Faktoren bei Zusammenlagerung von RNA-Protein-Komplexen in vivo beitragen.
microRNAs in chronic pain
(2016)
Chronic pain is a common problem in clinical practice, not well understood clinically, and frequently tough to satisfactorily diagnose. Because the pathophysiology is so complex, finding effective treatments for people with chronic pain has been overall less than successful and typically reduced to an unsatisfactory trial-and-error process, all of which translates into a significant burden to society. Knowledge of the mechanisms underlying the development of chronic pain, and moreover why some patients experience pain and others not, may aid in developing specific treatment regimens. Although nerve injuries are major contributors to pain chronification, they cannot explain the entire phenomenon. Considerable research has underscored the importance of the immune system for the development and maintenance of chronic pain, albeit the exact factors regulating inflammatory reactions remain unclear. Understanding the putative molecular and cellular regulator switches of inflammatory reactions will open novel opportunities for immune modulatory analgesics with putatively higher specificity and less adverse effects. It has become clear that small, non- coding RNA molecules known as microRNAs are in fact potent regulators of many thousands of genes and possibly cross-communicate between cellular pathways in multiple systems acting as so-called “master-switches”. Aberrant expression of miRNAs is now implicated in numerous disorders, including nerve injuries as well as in inflammatory processes. Moreover, compelling evidence supports the idea that miRNAs also regulate pain, and in analogy to the oncology field aid in the differential diagnosis of disease subtypes. In fact, first reports describing characteristic miRNA expression profiles in blood or cerebrospinal fluid of patients with distinct pain conditions are starting to emerge, however evidence linking specific miRNA expression profiles to specific pain disorders is still insufficient. The present thesis aimed at first, identifying specific miRNA signatures in two distinct chronic pain conditions, namely peripheral neuropathies of different etiologies and fibromyalgia syndrome. Second, it aimed at identifying miRNA profiles to better understand potential factors that differentiate painful from painless neuropathies and third, study the mechanistic role of miRNAs in the pathophysiology of pain, to pave the way for new druggable targets.
Three studies were conducted in order to identify miRNA expression signatures that are characteristic for the given chronic pain disorder. The first study measured expression of miR-21, miR-146a and miR-155 in white blood cells, skin and nerve biopsies of patients with peripheral neuropathies. It shows that peripheral neuropathies of different etiologies are associated with increased peripheral miR-21 and miR-146a, but decreased miR-155 expression. More importantly, it was shown that painful neuropathies have increased sural nerve miR-21 and miR-155 expression, but reduced miR-146a and miR-155 expression in distal skin of painful neuropathies. These results point towards the potential use of miRNAs profiles to stratify painful neuropathies. The seconds study extends these findings and first analyzed the role of miR-132-3p in patients and subsequently in an animal model of neuropathic pain. Interestingly, miR-132-3p was upregulated in white blood cells and sural nerve biopsies of patients with painful neuropathies and in animals after spared nerve injury. Pharmacologically modulating the expression of miR-132-3p dose-dependently reversed pain behavior and pain aversion, indicating the pro-nociceptive effect of miR-132-3p in chronic pain. This study thus demonstrates the potential analgesic impact by modulating miRNA expression. Fibromyalgia is associated with chronic widespread pain and, at least in a subgroup, impairment in small nerve fiber morphology and function. Interestingly, the disease probably comprises subgroups with different underlying pathomechanisms. In accordance with this notion, the third study shows that fibromyalgia is associated with both aberrant white blood cell and cutaneous miRNA expression. Being the first of its kind, this study identified miR-let-7d and its downstream target IGF-1R as potential culprit for impaired small nerve fiber homeostasis in a subset of patients with decreased intra-epidermal nerve fiber density. The work presented in this thesis is a substantial contribution towards the goal of better characterizing chronic pain based on miRNA expression signatures and thus pave the way for new druggable targets.
The genetic information encoded with in the genes are transcribed and translated to give rise to
the functional proteins, which are building block of a cell. At first, it was thought that the
regulation of gene expression particularly occurs at the level of transcription by various
transcription factors. Recent discoveries have shown the vital role of gene regulation at the level
of RNA also known as post-transcriptional gene regulation (PTGR). Apart from non-coding RNAs
e.g. micro RNAs, various RNA binding proteins (RBPs) play essential role in PTGR. RBPs have
been implicated in different stages of mRNA life cycle ranging from splicing, processing,
transport, localization and decay. In last 20 years studies have shown the presence of hundreds
of RBPs across eukaryotic systems many of which are widely conserved. Given the rising number
of RBPs and their link to human diseases it is quite evident that RBPs have major role in cellular
processes and their regulation. The current study is aimed to describe the so far unknown
molecular mechanism of CCHC-type Zinc Finger Nucleic Acid Binding Protein (CNBP/ZNF9)
function in vivo.
CNBP is ubiquitously expressed across various human tissues and is a highly conserved RBP in
eukaryotes. It is required for embryonic development in mammals and has been implicated in
transcriptional as well as post-transcriptional gene regulation; however, its molecular function
and direct target genes remain elusive. Here, we use multiple systems-wide approaches to
identify CNBP targets and document the consequences of CNBP binding. We established CNBP as
a cytoplasmic RNA-binding-protein and used Photoactivatable Ribonucleoside Enhanced
Crosslinking and Immunoprecipitation (PAR-CLIP) to identify direct interactions of CNBP with
4178 mRNAs. CNBP preferentially bound a G-rich motif in the target mRNA coding sequences.
Functional analyses, including ribosome profiling, RNA sequencing, and luciferase assays
revealed the CNBP mode of action on target transcripts. CNBP binding was found to increase the
translational efficiency of its target genes. We hypothesize that this is consistent with an RNA
chaperone function of CNBP helping to resolve secondary structures, thus promoting
translation. Altogether this study provides a novel mechanism of CNBP function in vivo and acts
as a step-stone to study the individual CNBP targets that will bring us closer to understand the
disease onset.